EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Safety Profile of Systemic Therapy for the Management of Psoriasis in Patients With Diabetes Mellitus: Data From the BIOBADADERM Prospective Cohort

J J Lluch-Galcerá, J M Carrascosa, A González-Quesada, A Sahuquillo, R Rivera Díaz, M Llamas-Velasco, E Herrera-Acosta, I Belinchón, F J Gómez García, O Baniandrés-Rodríguez, D P Ruiz-Genao, J L López-Estebaranz und 24 weitere

Actas Dermo-Sifiliográficas · 2026

DOI: 10.1016/j.ad.2026.104688 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Actas Dermo-Sifiliográficas, 2026. Verfasst von J J Lluch-Galcerá und 35 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Hospital General de Granollers, Granollers, Spain; Universitat Autònoma de Barcelona, Departament de Medicina, Barcelona, …. Hauptthemen laut MEDLINE: Psoriasis, Diabetes Complications, Dermatologic Agents. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND OBJECTIVE: Patients with psoriasis and concomitant diabetes mellitus (DM) may be vulnerable to diabetes-related adverse events (DM-AEs). This study aimed to evaluate the incidence of DM-AEs associated with systemic treatments used in patients with psoriasis and DM. METHODS: We conducted a prospective cohort study using data from the BIOBADADERM registry. We calculated incidence rates (IRs) of DM-AEs for each systemic treatment class, including biologics (tumor necrosis factor [TNF] inhibitors, interleukin [IL]-12/23 inhibitors, IL-17 inhibitors, and IL-23 inhibitors), conventional systemic therapies (methotrexate [MTX], cyclosporine, and acitretin), and apremilast (APR). The primary outcome was the adjusted incidence rate ratio (aIRR) for DM-AEs comparing patients receiving MTX with those receiving other systemic therapies using Poisson regression models adjusted for potential confounders. RESULTS: The study included 732 patients, 1401 treatment cycles, and 2865 person-years (PYs) of follow-up. APR (aIRR, 0.30; 95% CI, 0.10-0.60) was associated with a significantly lower risk of DM-AEs compared with MTX. Cyclosporine (aIRR, 7.50; 95% CI, 3.30-17.30) and acitretin (aIRR, 2.10; 95% CI, 1.20-3.70) were associated with a higher risk compared with MTX. CONCLUSIONS: Among patients with psoriasis and DM, APR was associated with a lower incidence of DM-AEs, whereas cyclosporine and acitretin were associated with higher incidences compared with MTX.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsoriasisDiabetes ComplicationsDermatologic AgentsHumansFemaleProspective StudiesMaleMiddle AgedAcitretinMethotrexateCyclosporineAdultThalidomideIncidenceRegistriesBiological ProductsImmunosuppressive Agents

Stichwörter der Autor:innen

BIOBADADERMDiabetes mellitusPsoriasisReal-world evidenceSafetySystemic therapy

Substanzen

AcitretinMethotrexateCyclosporineapremilastThalidomideBiological ProductsImmunosuppressive AgentsDermatologic Agents

Autor:innen und Institutionen

  • Department of Dermatology, Hospital General de Granollers, Granollers, Spain; Universitat Autònoma de Barcelona, Departament de Medicina, Barcelona, Spain.
  • Department of Dermatology, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, Departament de Medicina, Badalona, Barcelona, Spain. Electronic address: jmcarrascosac@hotmail.com.
  • Department of Dermatology, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Islas Canarias, Spain.
  • Department of Dermatology, Hospital Universitario y Politécnico La Fe, Valencia, Spain.
  • Department of Dermatology, Hospital Universitario 12 de Octubre, Universidad Complutense, Madrid, Spain.
  • Department of Dermatology, Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria de La Princesa (IIS-LP), Madrid, Spain.

Zitieren

APA

Lluch-Galcerá, J. J., Carrascosa, J. M., González-Quesada, A., Sahuquillo, A., Rivera Díaz, R., Llamas-Velasco, M., Herrera-Acosta, E., Belinchón, I., Gómez García, F. J., Baniandrés-Rodríguez, O., Ruiz-Genao, D. P., López-Estebaranz, J. L., Rodríguez Fernández-Freire, L., de la Cueva Dobao, P., Ferrán Farrés, M., Mateu Puchades, A., Ruiz-Villaverde, R., Riera-Monroig, J., Ara-Martín, M., …, & García-Doval, I. (2026). Safety Profile of Systemic Therapy for the Management of Psoriasis in Patients With Diabetes Mellitus: Data From the BIOBADADERM Prospective Cohort. Actas Dermo-Sifiliográficas. https://doi.org/10.1016/j.ad.2026.104688

Vancouver

Lluch-Galcerá JJ, Carrascosa JM, González-Quesada A, Sahuquillo A, Rivera Díaz R, Llamas-Velasco M, et al. Safety Profile of Systemic Therapy for the Management of Psoriasis in Patients With Diabetes Mellitus: Data From the BIOBADADERM Prospective Cohort. Actas Dermo-Sifiliográficas. 2026. doi:10.1016/j.ad.2026.104688

BibTeX
@article{LluchGalcer2026,
  author = {Lluch-Galcerá, J J and Carrascosa, J M and González-Quesada, A and Sahuquillo, A and Rivera Díaz, R and Llamas-Velasco, M and Herrera-Acosta, E and Belinchón, I and Gómez García, F J and Baniandrés-Rodríguez, O and Ruiz-Genao, D P and López-Estebaranz, J L and Rodríguez Fernández-Freire, L and de la Cueva Dobao, P and Ferrán Farrés, M and Mateu Puchades, A and Ruiz-Villaverde, R and Riera-Monroig, J and Ara-Martín, M and Roncero Riesco, M and Gracia-Cazaña, T and Abalde Pintos, M T and Pujol Marco, C and García-Donoso, C and Del Alcázar, E and Santamaría, C and Suárez Pérez, J and Rodríguez Sánchez, B and Díez-Madueño, K and Lezcano Biosca, V and Morales Callaghan, A M and Salgado-Boquete, L and Montes-Torres, A and González-Sixto, B and Descalzo, M Á and García-Doval, I},
  title = {Safety Profile of Systemic Therapy for the Management of Psoriasis in Patients With Diabetes Mellitus: Data From the BIOBADADERM Prospective Cohort},
  journal = {Actas Dermo-Sifiliográficas},
  year = {2026},
  doi = {10.1016/j.ad.2026.104688}
}
Kostenlos starten →